Despite a promising approach for certain leukemia patients, the path to market appears to be in question.
The therapy was developed at the National Cancer Institute, and Dr. Mackall said researchers did not know if a company would try to bring it to market.
https://www.nytimes.com/2017/11/20/health/cancer-immunotherapy-t-cells.html
More posts by Bruce Rychlik
Recent posts from Park Square Executive Search
